Analysts expect Stealth BioTherapeutics Corp (NASDAQ:MITO) to post earnings of ($0.02) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Stealth BioTherapeutics’ earnings. Stealth BioTherapeutics also posted earnings of ($0.02) per share during the same quarter last year. The firm is expected to announce its next quarterly earnings report on Thursday, November 4th.
On average, analysts expect that Stealth BioTherapeutics will report full-year earnings of ($0.07) per share for the current financial year, with EPS estimates ranging from ($0.07) to ($0.06). For the next fiscal year, analysts forecast that the business will post earnings of ($0.07) per share, with EPS estimates ranging from ($0.07) to ($0.06). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Thursday, August 5th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01).
Stealth BioTherapeutics stock opened at $1.41 on Friday. The business has a 50 day moving average of $1.33 and a 200-day moving average of $1.42. The company has a market capitalization of $81.19 million, a P/E ratio of -3.36 and a beta of 2.03. Stealth BioTherapeutics has a 1 year low of $1.06 and a 1 year high of $2.58.
Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC acquired a new stake in Stealth BioTherapeutics during the 1st quarter valued at approximately $40,000. HRT Financial LP bought a new stake in shares of Stealth BioTherapeutics in the 1st quarter valued at $28,000. Renaissance Technologies LLC increased its position in shares of Stealth BioTherapeutics by 55.1% during the first quarter. Renaissance Technologies LLC now owns 881,346 shares of the company’s stock worth $1,384,000 after buying an additional 313,182 shares during the period. Ikarian Capital LLC raised its stake in Stealth BioTherapeutics by 1,995.9% during the first quarter. Ikarian Capital LLC now owns 788,014 shares of the company’s stock worth $1,237,000 after buying an additional 750,417 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Stealth BioTherapeutics in the second quarter valued at $138,000. 1.70% of the stock is currently owned by institutional investors.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in George Town, Cayman Islands.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.